Dr Rama Suntharalingam

Kogularamanan (Rama) Suntharalingam obtained an MSci degree in Chemistry from Imperial College London. As an undergraduate, he conducted research in Professor Michael Hill's laboratory, investigating catalytic alkaline earth complexes. He subsequently completed his PhD at Imperial College London under the supervision of Professor Ramon Vilar, where he studied the interactions between metal complexes and G-quadruplex DNA. Following the award of the Misrock Postdoctoral Fellowship from the Koch Institute for Integrative Cancer Research, Rama joined Professor Stephen Lippard's research group at the Massachusetts Institute of Technology (MIT). There, his research focused on elucidating the mechanisms of action of third-row transition metal anticancer complexes and advancing their translation towards clinical application. Rama began his independent academic career in the Department of Chemistry at King's College London (KCL) after receiving a Leverhulme Early Career Fellowship. Following the successful completion of the fellowship, he was appointed Lecturer in Bioinorganic Chemistry at KCL. In 2019, Rama joined the University of Leicester as an Associate Professor in Inorganic Chemistry in the School of Chemistry. He was the Deputy Head of the School of Chemistry from 2023 to 2026. His current research focuses on the development of inorganic compounds and nanoscale delivery systems to target both bulk tumour cells and treatment-resistant cancer subpopulations. His contributions to the field have been recognised through awards, including the Royal Society of Chemistry (RSC) Inorganic Biochemistry Discussion Group Investigator Award and the RSC Dalton Young Researchers Award. 

The Suntharalingam research group aims to use the chemical and physical diversity offered by inorganic compounds to design and develop new generations of metallopharmaceuticals for the treatment of cancer and other diseases. The group also focuses on engineering new nano-material systems to deliver therapeutics to their site(s) of action.

I am/have been the PI or co-PI on a number of grants fellowships and studentships with a total value in excess of £2 million. Selected projects are listed below: EPSRC New Investigator Grant ‘Immuno-chemotherapeutic Metal Complexes for Cancer Stem Cell-Directed Therapy’ 2019-2022 (role: PI), Innovate UK-UKRI Knowledge Transfer Partnership with Food Attraction Ltd ‘To develop new production processes to extend the shelf-life of food products whilst maintaining product integrity’ 2021-2023 (role: co-PI), Rosetrees Trust 'Immuno-chemotherapeutic pro-drugs for cancer stem cell focused therapy' 2021-2022 (role: PI), Bone Cancer Research Trust 'Bone-seeking metal-based drugs to overcome chemotherapy-resistant osteosarcoma sub-populations' 2021-2023 (role: PI).

Metallopharmaceuticals for the treatment of cancer

Cancer stem cells (CSCs) are a distinct population of tumour cells that have the ability to self-renew, differentiate, and form metastatic tumours. CSCs effectively evade conventional chemotherapy and radiotherapy as these treatments specifically target fast growing cancer cells, and CSCs, due to their stem cell-like properties, divide more slowly. After surviving treatment, CSCs are able to regenerate the original tumour and/or produce invasive cancer cells that are able to colonise distant organs. For these reasons, CSCs are widely thought to be responsible for cancer relapse. Therefore, to provide a durable response and prevent tumour recurrence, chemotherapeutics must have the ability to remove the entire population of cancer cells, including CSCs. Therapeutic strategies capable of selectively killing CSCs and disrupting the microenvironments (niches) supporting these cells are the focus of several research programmes. Potential CSC therapeutic targets such as cell surface markers and various deregulated signalling pathways have been identified, but there is still no clinically approved drug that specifically kills CSCs. Many academia- and pharmaceutical-led studies aimed at developing chemical or biological anti-CSC agents are ongoing. Our group aims to harness the diversity and versatility offered by metals to develop inorganic compounds capable of potently and selectively killing CSCs (over bulk cancer cells and normal non-proliferating cells).

More generally, our group aims to use the structural, optical, redox, magnetic, and reactive diversity offered by metal-containing small molecules to design and develop new generations of metallopharmaceuticals for the treatment of cancer as well as other diseases. The group also focuses on engineering new nano-material systems to deliver therapeutics to their site(s) of action.

I have published 86 peer-reviewed papers in top-flight international journals (over 6500 citations, Scopus), and 62 independently as corresponding author. Of these papers, 19 papers are published in the very top chemistry journals (JACS, Angew. Chemie., Chem. Sci., Chem. Comm.). My current h-index is 33 (Scopus, WoS). I have also written 4 book chapters and hold 3 patents on the use of third-row transition metal-based complexes for cancer treatment.

Publications at Leicester only (post 2019)

1. Fang J, Wen S, Feng X, Ren H, Singh K, Xiao H*, Zhang L*, Suntharalingam K*, " Induction of Methuosis in Breast Cancer Stem Cells by a Cobalt(III) Complex Evokes Immunotherapeutic Response" Angewandte Chemie International Edition, 2026, accepted, DOI: 10.1002/anie.8926368.
2. Brown A, Cui M, Feng X, Singh K, Ortu F*, Xiao H*, Suntharalingam K*, “A Necroptosis-Inducing Nickel(II) Complex for Immunotherapeutic Activation of Breast Cancer Stem Cells” Inorganic Chemistry Frontiers, 2026, 13 (13), 5794-5806.
3. Feng X, Suntharalingam K*, “Interaction of bi-nuclear gallium(III) complexes with human serum albumin and impact on potency towards osteosarcoma stem cells” Dalton Transactions, 2026, 55, 7135-7141.
4. Ren H, Singh K, Suntharalingam K*, “Cyclometalated Rhodium(III) Polypyridyl Complexes with Anti-Cancer Stem Cell Activity” Organometallics, 2026, 45 (6), 628-632.
5. Feng X, Gordon M, Ren H, Ortu F*, Suntharalingam K*, “A gallium(III)-polypyridyl complex bearing chrysin with anti-osteosarcoma stem cell activity” Canadian Journal of Chemistry, 2026, DOI: 10.1139/cjc-2026-0111.
6. Feng X, Dhandore S, Liu Y, Singh K, Ortu F*, Suntharalingam K*, “Osteosarcoma Cell and Osteosarcoma Stem Cell Potent Immunogenic Bi-Nuclear Gallium(III) Complexes” Chemistry - A European Journal, 2025, 31, e202500747.
7. Josa D, Herrera-Ramírez P, Feng X, Gutiérrez A, Aguilà D, Grabulosa A, Martínez M, Suntharalingam K*, Gamez P*, “Cyclometalated half-sandwich iridium(III) and rhodium(III) complexes as efficient agents against cancer stem-cell mammospheres” Inorganic Chemistry Frontiers, 2025,12, 2404-2416.
8. Mouriki O, Passeri G, Singh K, Lamorte SD, Singh K, Suntharalingam K*, Kilpatrick AFR*, “Anti-breast cancer stem cell activity of titanocene complexes of non-steroidal anti-inflammatory drugs” Dalton Transactions, 2025, 54, 15389-15394.
9. Li Y, Hou Z, Xiao Z*, Lu C, Jin J*, He Y, Jin J, Suntharalingam K, “Modulating the Anticancer Activity of Square-Planar Platinum(II) Complex by Its Chelated Diphosphine” Applied Organometallic Chemistry, 2025, e7803.
10. Wang Y, Singh K, Lu C, Suntharalingam K*, “Anti-Cancer Stem Cell Properties of Square Planar Copper(II) Complexes with Vanillin Schiff Base Ligands” Molecules, 2025, 30(7), 1636.
11. Singh K, Northcote-Smith J, Feng X, Singh K, Suntharalingam K*, “The Anti-Cancer Stem Cell Properties of Copper(II)-Terpyridine Complexes with Attached Salicylaldehyde Moieties” ChemBioChem, 2025, 26, e202400703.
12. Fang J, Orobator ON, Olelewe C, Passeri G, Singh K, Awuah SG*, Suntharalingam K*, "A Breast Cancer Stem Active Cobalt(III)-Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential" Angewandte Chemie International Edition, 2024, 63, e202317940.
13. Li Y, Fang J, Singh K, Ortu F*, Suntharalingam K*, “An immunogenic anti-cancer stem cell binuclear copper(II)-flufenamic acid complex” Dalton Transactions, 2024, 53, 6410-6415.
14. Winfrey L, Yun L, Passeri G, Suntharalingam K*, Pulis AP*, “H₂O ⋅ B(C₆F₅)₃-Catalyzed para-Alkylation of Anilines with Alkenes Applied to Late-Stage Functionalization of Non-Steroidal Anti-Inflammatory Drugs” Chemistry - A European Journal, 2024, 30, e202303130.
15. Singh K, Singh K, Johnson A, Suntharalingam K*, “Anti-Breast Cancer Stem Cell Properties of Silver(I)-Non-steroidal Anti-Inflammatory Drug Complexes” European Journal of Inorganic Chemistry, 2024, e202400133.
16. Fang J, Gerschel P, Singh K, Apfel UP*, Suntharalingam K*, “Cobalt(III)-Macrocyclic Scaffolds with Anti-Cancer Stem Cell Activity” Molecules, 2024, 29(12), 2743.
17. Fang J, Singh K, Suntharalingam K*, “Anti-Cancer Stem Cell Cobalt(III)-Polypyridyl Complexes Containing Salicylic Acid” Inorganics, 2024, 12(8), 202.
18. Johnson A*, Olelewe C, Kim JH, Northcote-Smith J, Mertens RT, Passeri G, Singh K, Awuah SG*, Suntharalingam K*, “The anti-breast cancer stem cell properties of gold(I)-non-steroidal anti-inflammatory drug complexes” Chemical Science, 2023, 14, 557-565.
19. Osei PB, Northcote-Smith J, Fang J, Singh K, Ortu F*, Suntharalingam K*, “The Bulk Breast Cancer Cell and Breast Cancer Stem Cell Activity of Binuclear Copper(II)-Phenanthroline Complexes” Chemistry - A European Journal, 2023, e202301188.
20. Suntharalingam K*, “Modern Avenues in Metal-Nucleic Acid Chemistry, Vol. 25 of Metal Ions in Life Sciences” Inorganica Chimica Acta, 2023, 557, 121712.
21. Johnson A, Xiao F, Singh K, Ortu F*, Suntharalingam K*, “The Anti-Breast Cancer Stem Cell Potency of Copper(I)-Non-Steroidal Anti-Inflammatory Drug Complexes” Molecules, 2023, 28(17), 6401.
22. Singh K, Northcote-Smith J, Singh K, Suntharalingam K*, “Cancer stem cell activity of copper(II)-terpyridine complexes with aryl sulfonamide groups” Dalton Transactions, 2023, 52, 9694-9704.
23. Passeri G, Vincent RA, Xiao Z, Northcote-Smith J, Suntharalingam K*, “Encapsulation and Delivery of an Osteosarcoma Stem Cell Active Gallium(III)-Diflunisal Complex Using Polymeric Micelles” ChemMedChem, 2023, 18(4), e202200599.
24. Passeri G, Northcote-Smith J, Suntharalingam K*, “Payload Release Profile and Anti-Cancer Stem Cell Properties of Compositionally Different Polymeric Nanoparticles Containing a Copper(II) Complex” Molecules, 2023, 28(6), 2506.
25. Northcote-Smith J, Suntharalingam K*, “Targeting chemotherapy-resistant tumour sub-populations using inorganic chemistry: Anti-cancer stem cell metal complexes” Current Opinion in Chemical Biology 2023, 2023, 72, 102237.
26. Vincent RA, Passeri G, Northcote-Smith J, Singh K, Suntharalingam K*, “The Osteosarcoma Stem Cell Activity of a Gallium(III)-Phenanthroline Complex Appended to Salicylate” ChemBioChem, 2022, 23(24), e202200532.
27. Xiao Z*, Northcote-Smith J, Johnson A, Singh K, Suntharalingam K*, “The Cancer Stem Cell Potency of Group 10-Azadiphosphine Metal Complexes” European Journal of Inorganic Chemistry, 2022, 2022(32), e202200427.
28. Ryan AL, Northcote-Smith J, McKeon A, Roe A, O'Dowd P, Twamley B, Ní Chonghaile T, Suntharalingam K*, Griffith DM*, “A trans-Pt(II) hedgehog pathway inhibitor complex with cytotoxicity towards breast cancer stem cells and triple negative breast cancer cells” Dalton Transactions, 2022, 51(47), 18127-18135.
29. Passeri G, Northcote-Smith J, Perera R, Gubic N, Suntharalingam K*, “An Osteosarcoma Stem Cell Potent Nickel(II)-Polypyridyl Complex Containing Flufenamic Acid” Molecules, 2022, 27(10), 3277.
30. Chen CH, Liu Y-H, Eskandari A, Ghimire J, Lin L C-W, Fang Z-S, Wimley WC, Ulmschneider JP, Suntharalingam K*, Hu C-M J*, Ulmschneider MB*, “Integrated Design of a Membrane‐Lytic Peptide‐Based Intravenous Nanotherapeutic Suppresses Triple‐Negative Breast Cancer” Advanced Science, 2022, 9, 2105506.
31. Johnson A, Iffland-Mühlhaus L, Northcote-Smith J, Singh K, Ortu F*, Apfel U-P*, Suntharalingam K*, “A bioinspired redox-modulating copper(II)-macrocyclic complex bearing non-steroidal anti-inflammatory drugs with anti-cancer stem cell activity” Dalton Transactions, 2022, 51, 5904-5912.
32. Passeri G, Northcote-Smith J, Suntharalingam K*, “Delivery of an immunogenic cell death-inducing copper complex to cancer stem cells using polymeric nanoparticles” RSC Advances, 2022, 12(9), 5290–5299.
33. Xiao Z, Johnson A, Singh K, Suntharalingam K*, “The Discrete Breast Cancer Stem Cell Mammosphere Activity of Group 10-Bis(azadiphosphine) Metal Complexes” Angewandte Chemie International Edition, 2021, 60(12), 6704-6709.
34. Xiao Z, Passeri G, Northcote-Smith J, Singh K, Suntharalingam K*, “Osteosarcoma stem cell potent gallium(III)-polypyridyl complexes bearing diflunisal” Chemistry - A European Journal, 2021 27, 13846-13854.
35. Northcote-Smith J, Kaur P, Suntharalingam K*, “A Cancer Stem Cell Potent Copper(II) Complex with a S, N, S-Schiff base Ligand and Bathophenanthroline” European Journal of Inorganic Chemistry, 2021, 2021, 1770-1775.
36. Johnson A*, Iffland L, Singh K, Apfel U-P*, Suntharalingam K*, “A dithiacyclam-coordinated silver(I) polymer with anti-cancer stem cell activity” Dalton Transactions, 2021, 50, 5779-5783.
37. Johnson A, Northcote-Smith J, Suntharalingam K*, “Emerging Metallopharmaceuticals for the Treatment of Cancer” Trends in Chemistry, 2021, 3(1), 47-58.
38. Northcote-Smith J, Johnson A, Singh K, Ortu F*, Suntharalingam K*, “Breast cancer stem cell active copper(II) complexes with naphthol schiff base and polypyridyl ligands” Inorganics, 2021, 9(1), 5, 1-13.
39. Feld C, Johnson A, Xiao Z, Suntharalingam K*, “Breast cancer stem cell potency of nickel(II)‐polypyridyl complexes containing non‐steroidal anti‐inflammatory drugs” Chemistry - A European Journal, 2020, 26, 14011-14017.
40. Eskandari A, Flamme M, Xiao Z, Suntharalingam K*, “The Bulk Osteosarcoma and Osteosarcoma Stem Cell Activity of a Necroptosis‐Inducing Nickel(II)–Phenanthroline Complex” ChemBioChem, 2020, 21, 2854-2860.
41. Eskandari A, Kundu A, Johnson A, Karmakar S, Ghosh S*, Suntharalingam K*, “A tri-metallic palladium complex with breast cancer stem cell potency” Dalton Transactions, 2020, 49, 4211-4215.
42. Robin P, Singh K, Suntharalingam K*, “Gallium(III)-polypyridyl complexes as anti-osteosarcoma stem cell agents” Chemical Communications, 2020, 56, 1509-1512.
43. Kaur P, Johnson A, Northcote-Smith J, Lu C, Suntharalingam K*, “Immunogenic Cell Death of Breast Cancer Stem Cells by an Endoplasmic Reticulum‐Targeting Copper(II) Complex” ChemBioChem, 2020, 21, 3618-3624.
44. Eskandari A, Suntharalingam K*, “A reactive oxygen species-generating, cancer stem cell-potent manganese(II) complex and its encapsulation into polymeric nanoparticles” Chemical Science, 2019, 10, 7792-7800.
45. Eskandari A, Kundu A, Ghosh S*, Suntharalingam K*, “A Triangular Platinum(II) Multinuclear Complex with Cytotoxicity Towards Breast Cancer Stem Cells” Angewandte Chemie International Edition, 2019, 58, 12059-12064.
46. Apfel U-P*, Suntharalingam K*, “Bioinspired Reactivity and Coordination Chemistry” Dalton Transactions, 2019, 48, 5859-5860.
47. Zheng P, Eskandari A, Lu C, Laws K, Aldous L, Suntharalingam K*, “Biophysical analysis of cancer stem cell-potent copper(II) coordination complexes” Dalton Transactions, 2019, 48, 5892-5896.
48. Shin J, Eskandari A, Suntharalingam K*, “Modulating the Chemical and Biological Properties of Cancer Stem Cell-Potent Copper(II)-Nonsteroidal Anti-Inflammatory Drug Complexes” Molecules, 2019, 24(9), 1677.

Selected ten publications

Fang J, Wen S, Feng X, Ren H, Singh K, Xiao H*, Zhang L*, Suntharalingam K*, " Induction of Methuosis in Breast Cancer Stem Cells by a Cobalt(III) Complex Evokes Immunotherapeutic Response" Angewandte Chemie International Edition, 2026, accepted, DOI: 10.1002/anie.8926368.

Fang J, Orobator ON, Olelewe C, Passeri G, Singh K, Awuah SG*, Suntharalingam K*, "A Breast Cancer Stem Active Cobalt(III)-Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential" Angewandte Chemie International Edition, 2024, e202317940. DOI: 10.1002/anie.202317940.

Johnson A, Olelewe C, Kim JH, Northcote-Smith J, Mertens RT, Passeri G, Singh K, Awuah SG*, Suntharalingam K*, “The anti-breast cancer stem cell properties of gold(i)-non-steroidal anti-inflammatory drug complexes” Chemical Science, 2023, 14, 557-565.

Xiao Z, Johnson A, Singh K, Suntharalingam K*, "The Discrete Breast Cancer Stem Cell Mammosphere Activity of Group 10-Bis(azadiphosphine) Metal Complexes" Angewandte Chemie International Edition, 2021, 60, 6704-6709.

Eskandari A, Kundu A, Ghosh S*, Suntharalingam K*, "A Triangular Platinum(II) Multinuclear Complex with Cytotoxicity Towards Breast Cancer Stem Cells" Angewandte Chemie International Edition, 2019, 58, 12059-12064.

Eskandari A, Suntharalingam K*, "A reactive oxygen species-generating, cancer stem cell-potent manganese(II) complex and its encapsulation into polymeric nanoparticles" Chemical Science, 2019, 10, 7792-7800.

Laws K, Bineva-Todd G, Eskandari A, Lu C, O'Reilly N, Suntharalingam K*, "A Copper(II)-Phenanthroline Metallopeptide that Targets and Disrupts Mitochondrial Function in Breast Cancer Stem Cells" Angewandte Chemie International Edition, 2018 57, 287-291.

Boodram NJ, Mcgregor IJ, Bruno PM, Hemann MT, Suntharalingam K*, "Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes" Angewandte Chemie International Edition, 2016, 55, 2845-2850.

Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng Y, Page JE, Hemann MT, Lippard SJ, "Necroptosis-Inducing Rhenium(V) Oxo Complexes" Journal of the American Chemical Society, 2015, 137, 2967-2974

Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng Y, Hemann MT, Lippard SJ, "A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex" Journal of the American Chemical Society, 2014, 136, 14413-14416.

Bioinorganic Chemistry, Chemical Biology, Cancer Biology, Nanotechnology, Immunotherapy, Stem Cells

PhD and Postdoctoral researcher supervision. I have supervised 10 PhD students to completion, 6 as their primary supervisor and 4 as their secondary supervisor. I currently supervise 5 PhD students as the primary supervisor and 3 PhD students as the secondary supervisor. I have also supervised and mentored 6 postdoctoral researchers, all of whom now lead independent research groups in Universities in the UK, China, and South Africa. 

Undergraduate mentorship. I have successfully supervised 25 final year project students to completion (at University of Leicester and King’s College London). These efforts have led to >15 publications in high-ranked, peer-reviewed, Chemistry journals. Eight of the students were awarded graduation prizes as a result of the work they conducted under my supervision. I have also supervised two M1 year students from ENS Paris and ENS Lyon, and two M2 year students from the University of Strasbourg and Universität Leipzig through the ERAMUS+ programme. All of the undergraduate students I have supervised have gone on to undertake PhD studies at universities across Europe and North America or undertake jobs within the teaching, finance, marketing, commerce or civil service sectors.

Chemistry BSc and MChem degrees Modules:  Inorganic Chemistry (CH2202), Inorganic Chemistry (CH2202 DLI Module Leader), Bioinorganic Chemistry (CH4208 Module Leader)

Previously: General Chemistry (CH1200), Advanced Inorganic Chemistry (CH3202 DLI)

Drug discovery, Cancer, Immunotherapy, Nanotechnology.

Commissions of Trust
2025 - present: Local Organising Committee for the International Conference on Biological Inorganic Chemistry in 2027 (ICBIC)
2022 - present: Royal Society of Chemistry Inorganic Biochemistry Discussion Group (IBDG) Committee Member
2021 - present: EPSRC Peer Review College Member
2025 - present: Advisory Board for Chemistry Proceedings (MDPI)
2021 - present: Associate Editor for Frontiers in Immunology 
2020 - present: Editorial Board Section Member for Molecules (MDPI)
2018 - present: Guest Editor for Dalton Transactions (Royal Society of Chemistry)
2020 - 2022: Guest Editor for Cancers (MDPI)
2019 - 2020: Guest Editor for Molecules (MDPI)
2016 - present: EPSRC, BBSRC, MRC, Natural Sciences and Engineering Research Council of Canada, Czech Science Foundation, and Poland National Science Centre grant reviewer
2016 - present: PhD internal/external/chair examiner for >20 students so far (at Universities of Leeds, Hull, Sheffield, Leicester, East Anglia, Imperial College London, KCL, Francis Crick Institute, University of Cape Town, Technological University Dublin, Indian Institute of Science, Indian Institute of Technology Kanpur, and Tata Institute of Fundamental Research)

2020: Inorganic Biochemistry Discussion Group Investigator Award (Royal Society of Chemistry)

2018: Rising Star in Coordination Chemistry Award Lecture (International Conference in Coordination Chemistry Committee)

2016: 175 Faces of Chemistry (Royal Society of Chemistry)

2014: Leverhulme Early Career Fellowship (Leverhulme Trust)

2014: Dalton Young Researchers Award (Royal Society of Chemistry)

2014: Imperial College London Junior Research Fellowship (declined)

2012: Misrock Postdoctoral Fellowship (Misrock Foundation)

2012: Irish Research Council for Science Engineering and Technology Postdoctoral Fellowship (declined)

2009: Imperial College London-University of Hong Kong PhD Travelling Scholarship

2008: DTA-EPSRC PhD Scholarship

2008: HVA Briscoe Prize for Excellence in Inorganic Chemistry

2008: Enovik-Degussa Prize MSci Presentation Prize

2007: GlaxoSmithkline Beecham Pharmaceuticals Prize in Practical Inorganic Chemistry

2007: Nuffield Foundation Undergraduate Research Bursary

I have given several invited departmental lectures on my independent work, including at The Francis Crick Institute, University College London, Imperial College London, Trinity College Dublin, Ruhr-Universität Bochum, Institute of Chemistry Chinese Academy of Sciences, Dalian University of Technology, Technological University Dublin, Royal College of Surgeons in Ireland, IIT Kanpur, Beijing University of Chemical Technology, Jiaxing University, Universities of St. Andrews, Sheffield, Newcastle, Bath, Nottingham, Salford, East Anglia, and Hull.

I have also given >20 invited, keynote or plenary lectures at national and international conferences including the Inorganic Biochemistry Discussion Group Meeting, RSC Chemistry, Stem Cells & Regenerative Medicine Symposium, RSC Sir Geoffrey Wilkinson Dalton Poster Symposium, International Conference on Coordination Chemistry (Rising Star in Coordination Chemistry Award Lecture), European Biological Inorganic Chemistry Conference (x2), Spanish Bioinorganic Scientific Meeting, Wiley Metal Complexes for Biomedical Applications Symposium, Metals in Medicine Gordon Research Conference, Bone Cancer Research Trust Conference, Meeting of Inorganic Chemists Recently Appointed, Pacifichem, Canada-UK Joint Symposium on Inorganic Chemistry, Canadian Chemistry Conference and Exhibition (x2). I have also been invited to give a keynote lecture at the International Symposium on Bioorganometallic Chemistry in Poland in 2027.

Bioinorganic Chemistry, Chemical Biology, Cancer Biology, Nanotechnology, Immunotherapy, Stem Cells

MSci (Imperial College London)

PhD (Imperial College London)

Postdoctoral Misrock Fellowship (Massachusetts Institute of Technology and The Koch Institute for Integrative Cancer Research)

PGCAPHE (King's College London)